Long-term Treatment Outcome of Intravitreal Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
10.3341/jkos.2018.59.3.238
- Author:
Ye Ji KIM
1
;
Sang Yun HAN
;
Jong Woo KIM
;
Chul Gu KIM
;
Dong Won LEE
;
Jae Hui KIM
Author Information
1. Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. kjh7997@daum.net
- Publication Type:Original Article
- Keywords:
Aflibercept;
Age-related macular degeneration;
Choroidal neovascularization;
Long-term;
Polypoidal choroidal vasculopathy
- MeSH:
Choroid;
Choroidal Neovascularization;
Diagnosis;
Humans;
Macular Degeneration;
Medical Records;
Methods;
Retrospective Studies;
Treatment Outcome;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2018;59(3):238-245
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate long-term treatment outcomes of intravitreal aflibercept monotherapy for polypoidal choroidal vasculopathy (PCV). METHODS: A retrospective review of medical records was performed with 46 patients who were diagnosed with PCV and treated with aflibercept monotherapy for 24 months. Best-corrected visual acuity (BCVA) values measured at diagnosis, 3 months, 12 months, and 24 months were compared. Baseline morphological factors associated with the 24 month BCVA were additionally investigated. RESULTS: The mean age of the patients was 65.8 ± 7.9 years. The patients were treated with a mean of 7.0 ± 2.3 aflibercept injections. The mean logarithm of the minimal angle of resolution (logMAR) BCVA at diagnosis, 3 months, 12 months, and 24 months was 0.56 ± 0.40, 0.36 ± 0.36, 0.45 ± 0.42, and 0.52 ± 0.47, respectively. When compared with baseline values, the BCVA was significantly improved at 3 months (p < 0.001) and 12 months (p = 0.022). However, the value at 24 months was not significantly different (p = 1.000). The BCVA was improved or maintained in 35 eyes (76.1%). Extrafoveal polypoidal lesions were associated with a better 24 month visual outcome than subfoveal/juxtafoveal lesions. CONCLUSIONS: Aflibercept monotherapy was found to be an effective method to maintain or improve long-term visual acuity in PCV patients. The location of polypoidal lesions was a predictive factor for long-term visual outcomes.
